December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.310 +0.030 (+0.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
News headline image
Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics: Q4 Earnings Insights ↗
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: Aldeyra Therapeutics Q4 Earnings ↗
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc
Via Business Wire
News headline image
Earnings Scheduled For March 17, 2022 ↗
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
News headline image
Aldeyra Therapeutics Earnings Preview ↗
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
From Aldeyra Therapeutics
Via Business Wire
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference
From Aldeyra Therapeutics
Via Business Wire
News headline image
Aldeyra Therapeutics Announces Publication Of Phase 2 Clinical Trial Of Reproxalap In Allergen Chamber Model ↗
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today... 
Via Benzinga
News headline image
Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Rite Aid Shares Spike Higher ↗
Toward the end of trading Tuesday, the Dow traded up 1.52% to 35,463.11 while the NASDAQ rose 2.10% to 15,295.45. The S&P also rose, gaining 1.55% to 4,638.74. The U.S. has... 
Via Benzinga
News headline image
55 Biggest Movers From Yesterday ↗
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Rises 3%; Aldeyra Therapeutics Shares Slide ↗
Midway through trading Tuesday, the Dow traded up 1.15% to 35,332.22 while the NASDAQ rose 0.94% to 15,122.12. The S&P also rose, gaining 0.80% to 4,605.08. The U.S. has the... 
Via Benzinga
News headline image
38 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
Via Benzinga
News headline image
Stocks Set to Snap Selloff, Dow Eyes Triple-Digit Pop ↗
The major benchmarks look set to snap their three-day losing streak today, as investors reassess their anxieties over the fast-spreading omicron variant. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock moved upwards by 75.98% to $4.47 during Tuesday's pre-market session. The company's market cap stands at $62.8... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
News headline image
10 Biggest Price Target Changes For Tuesday ↗
B of A Securities lifted the price target on Micron Technology, Inc. (NASDAQ: 
Via Benzinga
News headline image
26 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.